domvanalimab,etrumadenant,zimberelimab
otsuka,arcus biosciences,gilead
['etrumadenant', 'zimberelimab', 'lung', 'nsclc', 'domvana', 'sclc']
domvanalimab + zimberelimab etrumadenant versus zimberelimab in first-line, metastatic, pd-l1-high non-small cell lung cancer (nsclc) exciting results, but #challenge try saying that 5 times fast! #asco2023
All the latest news, updates, guidelines, board review pearls, exam tips in the field of Hematology Oncology